3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
19
Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Neoplasm Metastasis
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer
2
Small Cell Lung Carcinoma
1
Recurrence
1
Prostate Adenocarcinoma
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Follicular
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Bulbo-Spinal Atrophy, X-Linked
1
Bites and Stings
1
Advanced Prostate Cancer
1
Adenocarcinoma
1
Interventions
fludarabine
10
Specimen Handling
8
Cytarabine
8
Cyclophosphamide
8
Biopsy
8
fludarabine phosphate
7
Whole-Body Irradiation
7
venetoclax
6
Injections
6
Busulfan
6
Azacitidine
6
Mycophenolic Acid
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
decitabine and cedazuridine drug combination
4
X-Rays
4
Tacrolimus
4
Stem Cell Transplantation
4
Cyclosporine
4
CPX-351
4
Peripheral Blood Stem Cell Transplantation
3
Magnetic Resonance Spectroscopy
3
Idarubicin
3
Decitabine
3
treosulfan
2
ruxolitinib
2
luspatercept
2
ivosidenib
2
gilteritinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
enzalutamide
×
30 days
×
Clear all
No trials found.